AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, ...

Smart healthtech wearable devices are trending but are these effective and accurate We reached out to a doctor who explained ...

The innovation showcased at CES highlights how practical solutions can meet niche, but impactful, health challenges. These ...

We're talking about current issues in atrial fibrillation management. Professor Wellens, I've followed your work with great admiration over the years. Can you tell me how you see the field of ...

According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making significant ...

We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where AtriCure, Inc. (NASDAQ:ATRC) stands against the other stocks that ...

AI reveals hidden patterns in ECGs that human experts can't see, transforming a century-old clinical tool into a powerful ...

US veterans with chronic cardiovascular conditions experiencing homelessness and unstable housing have lower outpatient care utilization.

Rakovina Therapeutics Inc. , a biopharmaceutical company at the forefront of AI-driven drug discovery, yesterday commented on the announcement of a $500 billion private-sector investment into AI ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...